Stammdaten
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Unternehmen & Branche
| Name | Accustem Sciences Inc. |
|---|---|
| Ticker | ACUT |
| CIK | 0001850767 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | 00444A101 |
|---|---|
| ISIN | US00444A1016 |
| Typ | Common Stock |
| Marktkapitalisierung | 5,1 Mio. USD |
| Beta | 2,45 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -1,756,096 | -0.12 | 1,549,446 | -3,401,625 | |
| 2025-09-30 | 10-Q | -399,897 | -0.02 | 1,573,247 | -2,910,910 | |
| 2025-06-30 | 10-Q | -401,403 | -0.02 | 1,613,537 | -2,534,687 | |
| 2025-03-31 | 10-Q | -440,408 | -0.03 | 1,550,584 | -2,156,525 | |
| 2024-12-31 | 10-K | -1,505,102 | -0.13 | 50,851 | -3,313,224 | |
| 2024-09-30 | 10-Q | -328,174 | -0.03 | 103,819 | -3,193,634 | |
| 2024-06-30 | 10-Q | -278,225 | -0.02 | 139,660 | -2,884,306 | |
| 2024-03-31 | 10-Q | -526,602 | -0.05 | 50,941 | -2,620,014 | |
| 2023-12-31 | 10-K | -2,050,664 | -0.18 | 133,897 | -2,111,580 | |
| 2023-09-30 | 10-Q | -598,525 | -0.05 | 257,575 | -1,885,437 | |
| 2023-06-30 | 10-Q | -372,756 | -0.03 | 458,530 | -1,306,812 | |
| 2023-03-31 | 10-Q | -833,341 | -0.07 | 247,559 | -946,682 | |
| 2022-12-31 | 10-K | -3,746,419 | -0.34 | 939,689 | -139,550 | |
| 2022-09-30 | 10-Q | -899,125 | -0.08 | 1,622,658 | 797,724 | |
| 2022-06-30 | 10-Q | -1,078,226 | -0.10 | 2,381,956 | 1,650,566 | |
| 2022-03-31 | 10-Q | -790,534 | 3,252,126 | 2,691,017 | ||
| 2021-12-31 | 10-K | -670,614 | 1,353,373 | 650,673 | ||
| 2021-09-30 | 10-Q | -62,722 | 1,189,386 | |||
| 2021-06-30 | 10-Q | -50,537 | 1,260,207 | |||
| 2021-03-31 | 10-Q | -13,873 | 1,310,338 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2024. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| STUDIO INVESTMENT MANAGEMENT LLC | 30 | 14 | 100.00 |